RUNDC3A/SNAP25/Akt signaling mediates tumor progression and chemoresistance in gastric neuroendocrine carcinoma

Cell Death Dis. 2022 Oct 1;13(10):840. doi: 10.1038/s41419-022-05294-7.


Gastric neuroendocrine carcinoma (GNEC), a heterogeneous group of neuroendocrine neoplasms (NENs) derived from gastric neuroendocrine cells, has been shown to be more aggressive and chemoresistant in gastric cancer, which contributes to the poor prognosis. We analysed transcriptome profiles of tumor/non-tumor tissue from GNEC patients and GNEC cell lines to explore the underlying mechanisms. Our results suggest a critical role for synaptosomal-associated protein 25 kDa (SNAP25) in GNEC. SNAP25 was found to stabilize Akt via modulating its monoubiquitination. We further identified RUN domain containing 3A (RUNDC3A) as an upstream molecule that regulates SNAP25 expression, which is associated with tumor progression and chemoresistance in GNECs. Moreover, these findings were extended into multiple NENs including neuroendocrine carcinomas in the intestinal tract, lungs and pancreas. Identifying the RUNDC3A/SNAP25/Akt axis in NENs may provide a novel insight into the potential therapeutic target for patients with NENs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Neuroendocrine* / drug therapy
  • Carcinoma, Neuroendocrine* / genetics
  • Carcinoma, Neuroendocrine* / pathology
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Neuroendocrine Tumors* / metabolism
  • Pancreatic Neoplasms* / pathology
  • Proto-Oncogene Proteins c-akt / genetics
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / genetics
  • Stomach Neoplasms* / metabolism
  • Synaptosomal-Associated Protein 25


  • SNAP25 protein, human
  • Synaptosomal-Associated Protein 25
  • Proto-Oncogene Proteins c-akt